Study Details

Study to test the efficacy and safety of YM178 in subjects with symptoms of overactive bladder

This trial is complete
The study has ended normally, and participants are no longer being examined or treated (that is, the last participant's last visit has occurred). ID

The unique identification code given to each clinical study upon registration at

Astellas Study ID

The unique identification code given by the study sponsor.


EudraCT ID

The unique identification code given to each clinical study upon registration at EudraCT (European Union Drug Regulating Authorities Clinical Trials Database).



Overactive Bladder Disease


These clinical trials are done to learn if an experimental treatment helps participants who have a specific condition or disease. Phase 2 trials usually include a larger group of participants than Phase 1 trials.

Phase 2


18 years - N/A


Female & Male




A type of clinical study in which participants are assigned to groups that receive one or more intervention/treatment (or no intervention) so that researchers can evaluate the effects of the interventions on biomedical or health-related outcomes.


Trial Dates

Apr 2004 - Jan 2005


Double (Participant, Investigator)

Enrollment number


A randomized, double-blind, parallel group, proof of concept study of YM178 in comparison with placebo and tolterodine in patients with symptomatic overactive bladder

Study summary

Study documents

Study Documents, including study results, are available after a study is completed or terminated, according to Astellas Transparency policy.

Get More Information

Would you like more information about clinical trial sites that are recruiting participants for Study to test the efficacy and safety of YM178 in subjects with symptoms of overactive bladder? Contact us by filling our your information to the right and we’ll respond to you.

By clicking ["Continue/Submit"], you agree that Astellas may contact you by email with information to help you connect with clinical trial sites. While we can connect you to clinical trial sites, we cannot answer questions about any investigational therapy through email. Your consent to receiving emails is not a requirement to participate in a clinical trial or study. For more information, including how to unsubscribe at any time, see our Privacy Notice & Cookies Policy.


Site: 20

Prague, Czech Republic, 180 81

Site: 21

Usti nad Labem, Czech Republic, 40001

Site: 43

Miranda de Ebro, Spain, 09200

Site: 11

Gent, Belgium, 9000

Site: 25

Melnik, Czech Republic, 276 01

Site: 64

Bimingham, United Kingdom, B15 2TG

Site: 50

Lund, Sweden, 221 85

Site: 33

Hamburg, Germany, 20253

Site: 61

Swansea, United Kingdom, SA6 6NL

Site: 52

Uppsala, Sweden, 751 85

Site: 36

Koblenz, Germany, 56068

Site: 32

Bad Ems, Germany, 56130

Site: 31

Trier, Germany, 54290

Site: 42

Alzira-Valencia, Spain, 46600

Site: 60

Sheffield, United Kingdom, S10 2JF

Site: 35

Frankfurt, Germany, 60326

Site: 55

Gotenburg, Sweden, 413 45

Site: 40

Madrid, Spain, 28046

Site: 34

Hagenow, Germany, 19230

Site: 23

Usti nad Labem, Czech Republic, 401 13

Site: 63

London, United Kingdom, W1P 7PN

Site: 13

Edegem, Belgium, 2650

Site: 10

Leuven, Belgium, 3000

Site: 62

London, United Kingdom, N19 5LW

Site: 22

Prague, Czech Republic, 128 08

Site: 24

Prague, Czech Republic, 140 59

Site: 30

Emmendingen, Germany, 79312

Site: 12

Brussels, Belgium, 1090

Site: 51

Stockholm, Sweden, 141 86

Site: 53

Linkoping, Sweden, 582 24